Exelixis, Inc. (EXEL) reported robust first-quarter 2026 results, with total revenues reaching $611 million, driven primarily by its cabozantinib franchise, which generated $555 million in net product revenues. Notably, CABOMETYX, the leading tyrosine kinase inhibitor (TKI) for renal cell carcinoma, saw an 8% year-over-year revenue increase, alongside a significant 12.5% growth in global cabozantinib revenues. The company also highlighted a strategic focus on expanding its sales team in gastrointestinal oncology to bolster CABOMETYX’s market position ahead of the anticipated launch of its new drug ZANZA.
The financial performance underscores Exelixis’s strong foothold in the oncology market, particularly as it prepares for a December 2026 decision on the new drug application for ZANZA in colorectal cancer. With ongoing pivotal trials and an expanding pipeline, the company is well-positioned to capitalize on the $1.5 billion market opportunity in third-line-plus colorectal cancer.
Investors should note Exelixis’s commitment to shareholder returns, as evidenced by $430.8 million in share repurchases during the quarter and a new $50 million buyback authorization. This strategic capital allocation, coupled with strong revenue growth, positions Exelixis favorably for continued market expansion and shareholder value enhancement.
Source: fool.com